tonaquatic/iStock via Getty Images
- Geron (NASDAQ:GERN) announced on Tuesday the pricing of an underwritten offering consisting of ~42M common shares at a price of $3.00/share and pre-funded warrants to purchase ~8M common shares.
- According to GERN, the pre-funded warrants are being sold at a price of $2.999/pre-funded warrant.
- GERN expects proceeds of ~$150M from the underwritten offering.
- All of the securities in the offering are to be sold by GERN, the company said.
- The offering is expected to close on or about March 21, 2024, GERN added.
- The company expects to use the offering proceeds to fund the potential commercialization of imetelstat in low or intermediate-1 risk myelodysplastic syndromes in the U.S., and potential launch and commercialization of imetelstat in low or intermediate-1 risk myelodysplastic syndromes in the EU, among other things.
- Press Release
More on Geron
- Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy
- Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA
- Geron Corporation (GERN) Q4 2023 Earnings Call Transcript
- Geron surges after FDA AdCom backing for lead drug
- Biggest stock movers today: RIVN, ADBE, GERN, and more